Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Quality of Life Study in Type 2 Diabetes
NCT02719132Phase 4Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Planned start Jul 2016; status: withdrawn.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02719132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719132.